183 related articles for article (PubMed ID: 30994218)
1. Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.
Hartmann L; Haferlach C; Meggendorfer M; Kern W; Haferlach T; Stengel A
Genes Chromosomes Cancer; 2019 Oct; 58(10):698-704. PubMed ID: 30994218
[TBL] [Abstract][Full Text] [Related]
2. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
3. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
4. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
5. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
[TBL] [Abstract][Full Text] [Related]
6. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.
Nguyen-Khac F; Lesty C; Eclache V; Couronné L; Kosmider O; Andrieux J; Collonge-Rame MA; Penther D; Lafage M; Bilhou-Nabera C; Chapiro E; Mozziconacci MJ; Mugneret F; Gachard N; Nadal N; Lippert E; Struski S; Dastugue N; Cabrol C; Bernard OA;
Genes Chromosomes Cancer; 2010 Oct; 49(10):919-27. PubMed ID: 20629097
[TBL] [Abstract][Full Text] [Related]
8. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of
Abbas HA; Ayoub E; Sun H; Kanagal-Shamanna R; Short NJ; Issa G; Yilmaz M; Pierce S; Rivera D; Cham B; Wing S; Li Z; Hammond D; Jabbour E; Borthakur G; Garcia-Manero G; Andreeff M; Daver N; Kadia T; Konopleva M; DiNardo C; Ravandi F
Leuk Lymphoma; 2022 Dec; 63(13):3105-3116. PubMed ID: 36089905
[TBL] [Abstract][Full Text] [Related]
10. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
11. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias.
Fischer K; Fröhling S; Scherer SW; McAllister Brown J; Scholl C; Stilgenbauer S; Tsui LC; Lichter P; Döhner H
Blood; 1997 Mar; 89(6):2036-41. PubMed ID: 9058725
[TBL] [Abstract][Full Text] [Related]
12. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
13. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.
Herold T; Metzeler KH; Vosberg S; Hartmann L; Jurinovic V; Opatz S; Konstandin NP; Schneider S; Zellmeier E; Ksienzyk B; Graf A; Krebs S; Blum H; Cristina Sauerland M; Büchner T; Berdel WE; Wörmann BJ; Mansmann U; Hiddemann W; Bohlander SK; Spiekermann K; Greif PA
Genes Chromosomes Cancer; 2017 Jan; 56(1):75-86. PubMed ID: 27636548
[TBL] [Abstract][Full Text] [Related]
15. De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics.
Ismael O; Shimada A; Hama A; Elshazley M; Muramatsu H; Goto A; Sakaguchi H; Tanaka M; Takahashi Y; Yinyan X; Fukuda M; Miyajima Y; Yamashita Y; Horibe K; Hanada R; Ito M; Kojima S
Br J Haematol; 2012 Jul; 158(1):129-37. PubMed ID: 22571758
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
[TBL] [Abstract][Full Text] [Related]
17. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.
Traina F; Visconte V; Jankowska AM; Makishima H; O'Keefe CL; Elson P; Han Y; Hsieh FH; Sekeres MA; Mali RS; Kalaycio M; Lichtin AE; Advani AS; Duong HK; Copelan E; Kapur R; Olalla Saad ST; Maciejewski JP; Tiu RV
PLoS One; 2012; 7(8):e43090. PubMed ID: 22905207
[TBL] [Abstract][Full Text] [Related]
18. Somatic SETBP1 mutations in myeloid neoplasms.
Makishima H
Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
[TBL] [Abstract][Full Text] [Related]
19. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.
McNerney ME; Brown CD; Wang X; Bartom ET; Karmakar S; Bandlamudi C; Yu S; Ko J; Sandall BP; Stricker T; Anastasi J; Grossman RL; Cunningham JM; Le Beau MM; White KP
Blood; 2013 Feb; 121(6):975-83. PubMed ID: 23212519
[TBL] [Abstract][Full Text] [Related]
20. Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.
Larsson N; Lilljebjörn H; Lassen C; Johansson B; Fioretos T
Eur J Haematol; 2012 Feb; 88(2):136-43. PubMed ID: 21933280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
